Further, roles have also been proposed for IL-1 cytokines in MAS pathogenesis because IL-1Ra is currently used off-label for the treatment of CSS, with patients responding well to high doses (Miettunen et al., 2011; Bruck et al., 2011; Phadke et al., 2021). Here, IL1B is linked to macrophage activation syndrome.